Showing results (1-10 of 370) with videos related to
Sort By:
Pageof 37
European Journal of Cancer (Oxford, England : 1990)|December 6, 2008
Micrometastatic disease in breast cancer: clinical implicationsMichail Ignatiadis, Vassilis Georgoulias, Dimitris MavroudisCurrent Opinion in Obstetrics & Gynecology|January 17, 2008
Circulating tumor cells in breast cancerMichail Ignatiadis, Vassilis Georgoulias, Dimitris MavroudisClinical Biochemistry|August 24, 2006
Detection of Mammaglobin A-mRNA-positive circulating tumor cells in peripheral blood of patients with operable breast cancer with nested RT-PCRMaria Ntoulia, Aliki Stathopoulou, Michail Ignatiadis, et al.Expert Opinion on Pharmacotherapy|September 23, 2008
Paclitaxel and docetaxel in the treatment of breast cancerEmmanouel Saloustros, Dimitris Mavroudis, Vassilis GeorgouliasAnticancer Research|November 27, 2008
Gefitinib in combination with gemcitabine and vinorelbine in patients with metastatic breast cancer pre-treated with taxane and anthracycline chemotherapy: a phase I/II trialIoannis Gioulbasanis, Zacharenia Saridaki, Antonia Kalykaki, et al.Molecular Medicine (Cambridge, Mass.)|May 23, 2007
Phosphorylation of FAK, PI-3K, and impaired actin organization in CK-positive micrometastatic breast cancer cellsGalatea Kallergi, Dimitris Mavroudis, Vassilis Georgoulias, et al.Clinical Breast Cancer|February 14, 2008
Molecular detection and prognostic value of circulating cytokeratin-19 messenger RNA-positive and HER2 messenger RNA-positive cells in the peripheral blood of women with early-stage breast cancerMichail Ignatiadis, Maria Perraki, Stella Apostolaki, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2008
Prognostic value of the molecular detection of circulating tumor cells using a multimarker reverse transcription-PCR assay for cytokeratin 19, mammaglobin A, and HER2 in early breast cancerMichail Ignatiadis, Galatea Kallergi, Maria Ntoulia, et al.Clinical Lung Cancer|December 16, 2005
Sequential versus alternating administration of cisplatin/etoposide and topotecan as first-line treatment in extensive-stage small-cell lung cancer: preliminary results of a Phase III Trial of the Hellenic Oncology Research GroupMichail Ignatiadis, Dimitris Mavroudis, Marinos Veslemes, et al.Anti-Cancer Drugs|November 1, 2006
Coadministration of oxaliplatin does not influence the pharmacokinetics of gemcitabinePeriklis Pappas, Dimitris Mavroudis, Martha Nikolaidou, et al.Pageof 37